JP2023524434A5 - - Google Patents

Info

Publication number
JP2023524434A5
JP2023524434A5 JP2022565781A JP2022565781A JP2023524434A5 JP 2023524434 A5 JP2023524434 A5 JP 2023524434A5 JP 2022565781 A JP2022565781 A JP 2022565781A JP 2022565781 A JP2022565781 A JP 2022565781A JP 2023524434 A5 JP2023524434 A5 JP 2023524434A5
Authority
JP
Japan
Prior art keywords
cells
icam3
cov
sars
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524434A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029608 external-priority patent/WO2021222385A1/en
Publication of JP2023524434A publication Critical patent/JP2023524434A/ja
Publication of JP2023524434A5 publication Critical patent/JP2023524434A5/ja
Pending legal-status Critical Current

Links

JP2022565781A 2020-04-29 2021-04-28 新規療法 Pending JP2023524434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017199P 2020-04-29 2020-04-29
US63/017,199 2020-04-29
PCT/US2021/029608 WO2021222385A1 (en) 2020-04-29 2021-04-28 Glucocorticoid receptor (gr) modulators for treating a sars-cov-2 virus

Publications (2)

Publication Number Publication Date
JP2023524434A JP2023524434A (ja) 2023-06-12
JP2023524434A5 true JP2023524434A5 (enExample) 2024-05-08

Family

ID=76270026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565781A Pending JP2023524434A (ja) 2020-04-29 2021-04-28 新規療法

Country Status (7)

Country Link
US (1) US20230172950A1 (enExample)
EP (1) EP4142736A1 (enExample)
JP (1) JP2023524434A (enExample)
KR (1) KR20230015927A (enExample)
CN (1) CN115666583A (enExample)
BR (1) BR112022021691A2 (enExample)
WO (1) WO2021222385A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540319A (ja) * 2021-11-05 2024-10-31 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肺粘膜炎症の処置のための低分子量ヒアルロン酸の使用
CN114028571B (zh) * 2021-11-18 2023-04-28 中国医学科学院基础医学研究所 含氮双膦酸盐联合糖皮质激素在预防或治疗病毒性肺炎中的应用
CN114099481B (zh) * 2022-01-28 2022-05-24 深圳湾实验室 雾化吸入型糖皮质激素纳米药物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
CA3168378A1 (en) * 2020-02-28 2021-09-02 Avm Biotechnology, Llc Lypmphocyte population and methods for producing same

Similar Documents

Publication Publication Date Title
Zhang et al. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
JP2023524434A5 (enExample)
Zhou et al. Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis
Zhang et al. Treg: a promising immunotherapeutic target in oral diseases
Almawi et al. An alternate mechanism of glucocorticoid anti‐proliferative effect: promotion of a Th2 cytokine‐secreting profile
Crome et al. Natural killer cells regulate diverse T cell responses
Zhou et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Wang et al. Regulatory T cells in autoimmune hepatitis: unveiling their roles in mouse models and patients
Gross et al. Regulatory functions of natural killer cells in multiple sclerosis
Erb et al. CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterization of target cell recognition by in vivo or in vitro activated CD4+ killer T cells.
Li et al. The role of immune cells in chronic HBV infection
Kin et al. It takes nerve to tell T and B cells what to do
Earle et al. In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation
Noble et al. IFN-γ and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles
Camacho et al. Inflammatory cytokines shape an altered immune response during myeloid malignancies
Morgan et al. Distinct effects of dexamethasone on human natural killer cell responses dependent on cytokines
US6277635B1 (en) Use of interleukin-10 to produce a population of suppressor cells
Acharya et al. Interleukin-17A promotes CD8+ T cell cytotoxicity to facilitate West Nile virus clearance
Calzada-Wack et al. Interleukin-10 drives human monocytes to CD16 positive macrophages
Strieter et al. Interleukin-2-induced tumor necrosis factor-alpha (TNF-α) gene expression in human alveolar macrophages and blood monocytes
Thomson et al. Prospective clinical testing of regulatory dendritic cells in organ transplantation
Qu et al. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
Murphy et al. The potential role of NK cells in the separation of graft‐versus‐tumor effects from graft‐versus‐host disease after allogeneic bone marrow transplantation
Ye et al. Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering
Luo et al. CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update